MashupMD

Mashup Score: 9

Subcutaneous Nivolumab for RCC: CheckMate 67T Practice-Changing Results | GU Oncology Now - 3 month(s) ago

Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.

Source: guoncologynow.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- GUOncologyNow
  
  📺 Watch @AlbigesL provide an overview of the CheckMate 67T trial, which compared the subcutaneous administration of #nivolumab with IV administration in patients with #RCC: https://t.co/hulmTOncUo Dr. Albiges highlights the study’s success in meeting its co-primary endpoints.